article
Use of plasmids for expression of proteins from the genus Leishmania in Escherichia coli: current state and perspectives
Registro en:
0175-7598
1432-0614
10.1016/j.pep.2017.11.005
Autor
Santos, Everaldo Silvino dos
Ribeiro, Vitor Troccoli
Leitão, Ana Laura Oliveira de Sá
Vasconcelos, Luan Tales Costa de Paiva
Oliveira Filho, Marcos Antônio
Martins, Daniella Regina Arantes
Sousa Júnior, Francisco Canindé de
Resumen
Leishmaniosis is caused by the protozoa of the genus Leishmania with a wide spectrum of clinical and epidemiological manifestations which are characterized into four clinical groups: cutaneous, mucocutaneous, diffuse cutaneous, and visceral. American visceral leishmaniosis (AVL) or visceral leishmaniosis (VL) has been known as the most severe form of the disease. However, despite the growing number of people exposed to the infection risk and the great effort done by the scientific community worldwide to significantly increase the knowledge about these diseases, there is no vaccine capable of preventing VL in humans. In this short review, we present some of the plasmids used for the expression of recombinant protein by Escherichia coli strains used mainly for the second generation of vaccines for leishmaniosis. It can be emphasized that currently,
these vectors and hosts play an important role in developing vaccine strategies against the disease. Indeed, use of the E. coli BL21 (DE) strain is remarkable mainly due to its characteristics for being a stable protein producer as well as the use of histidine tags for antigen purification